Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 79

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 79
---
2033. Liminatus’s innovative approach and intellectual property rights make it well-suited to capture a significant share of this growing market.

•

Furthermore, advances in research since the Business Combination Agreement was initially signed have strengthened the value proposition of the CD47 asset. Critical preclinical work, including CMC development and toxicity studies, has been completed, alongside independent research revealing potential new applications for the CD47 asset in mitigating age-related diseases, such as cardiovascular disease and obesity. These developments highlight CD47’s broad therapeutic potential, reinforcing the Business Combination’s importance and long-term value for stockholders.

In the course of its deliberations, in addition to the various other risks associated with the business of Liminatus, as described in the section titled “ Risk Factors ” appearing elsewhere in this proxy statement/ prospectus, the Iris Board also considered a variety of uncertainties, risks, and other potentially negative factors relevant to the Business Combination, including the following:

•

Macroeconomic uncertainty, including with respect to global and national supply chains, and the effects they could have on Liminatus’s revenues and financial performance.

•

The risk that Liminatus may not be able to execute on its business plan and realize its anticipated financial performance.

•

The risk that Liminatus’s products in development do not perform as expected, fail clinical trials, or are not approved by the U.S. Food and Drug Administration (“FDA”) or other applicable regulatory authorities .

•

Clinical trials are long and expensive, and the results of such are uncertain.

•

Liminatus is subject to continuing regulatory compliance by the FDA and other applicable regulatory authorities, which could result in negative effects on Liminatus if the regulatory environment changes or Liminatus fails to comply with regulatory requirements.

•

Liminatus’s brand and reputation are critical to its success, and any publicity, regardless of accuracy, that portrays Liminatus negatively could adversely impact operating results.

•

The risks and costs to Iris if the Business Combination is not completed, including the risk of diverting management’s focus and resources from other businesses combination opportunities, which could result in Iris being unable to effect a business combination within the completion window, which would require Iris to liquidate.

•

The risk that Iris’s stockholders may object to and challenge the Business Combination and take action that may prevent or delay the closing, including by voting against the Business Combination Proposal.

•

The terms of the Business Combination Agreement provide that Iris will not have any surviving remedies against Liminatus or its equityholders after the closing to recover for losses as a